Previous 10 | Next 10 |
BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer,...
2023-12-29 19:03:08 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Cell and gen...
2023-12-29 14:12:19 ET Summary The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have ...
2023-12-29 01:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-11 14:27:17 ET Summary Verve Therapeutics, Inc. released positive interim data from its phase 1b heart-1 study using VERVE-101 for treating HeFH patients; LDL-C reduced by as much as 55% after a single dose. IND clearance for VERVE-101 in the U.S. opens up the inclusion of...
2023-12-11 11:57:44 ET Summary Verve Therapeutics is a biotechnology company focused on developing single-course gene editing medicines for cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD). The company has advanced its first cardiovascular ...
BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten...
2023-11-30 13:19:51 ET Summary Verve Therapeutics is focused on developing in vivo gene editing therapies for cardiovascular disease. The company aims to disrupt the chronic care model for CVD by targeting genes related to atherosclerotic cardiovascular disease. Verve's interi...
2023-11-29 07:30:19 ET More on Verve Therapeutics Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve Therapeutics intends to raise cash through public offering Verve fall...
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of 12...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory cap...
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approac...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of car...